Pfizer Undergoes Major Leadership Reshuffle, Names Chris Boshoff as New R&D Chief

Pfizer has announced the appointment of Chris Boshoff as the new Chief Scientific Officer (CSO), taking over from Mikael Dolsten on January 1, 2024. Boshoff, who currently serves as Pfizer's Chief Oncology Officer and Executive Vice President, has been with the company for 11 years and has played a pivotal role in the development of 24 medicines across 30 indications. His appointment comes as part of a broader leadership reshuffle aimed at strengthening Pfizer's R&D pipeline, particularly in the oncology sector, and is viewed as a strategic move to address investor concerns and enhance innovation[1][2][3]. CEO Albert Bourla has praised Boshoff's leadership and his vision for the future of Pfizer's R&D, anticipating that he will lead significant advancements in therapeutic breakthroughs[1][3]. As Boshoff steps into this role, Roger Dansey is set to temporarily take over as Chief Oncology Officer, ensuring a smooth transition until a permanent successor is appointed[2][3].